Abstract

目的 探讨手术前肺癌患者血清中糖链抗原125(CA125)、神经元特异性烯醇化酶(NSE)、降钙素(CT)水平在肺癌诊断及预后中的意义.方法 92例肺癌患者进入该观察,其中Ⅰ期4例,Ⅱ期21例,Ⅲ期50例,Ⅳ期6例.所有患者均在手术治疗前抽血测定CA125、NSE、CT.同期30名健康体检者被选作对照组.结果 CA125、NSE、CT对肺癌诊断的敏感度分别为48.9%、21.7%、7.6%.CA125在各组肺癌血清中的测定值均显著高于健康体检者(P<0.05);NSE仅在小细胞肺癌组中高于健康体检者(P<0.01);CT在各组中与健康体检者无显著性差异.CA125正常组的术后3年生存率为66.0%(31/47),CA125升高组为44.4%(20/45),两者有显著性差异(P<0.05).血清NSE、CT升高组的术后3年生存率分别为45.0%(9/20)、42.8%(3/7),血清NSE、CT正常组分别为58.3%(42/72)、56.5%(48/85),二者相比无显著性差异(P>0.05).结论 CA125、NSE、CT对肺癌的诊断价值有限;术前CA125对手术治疗的肺癌患者有预后意义.

Objective To explore the clinical and prognostic values of serum carbohydrate antigen (CA125), neuron-specific enolase (NSE), calcitonin (CT) levels in patients with lung cancer before operation. Methods Ninety two untreated patients with lung cancer confirmed histologically were studied. Serum CA125, NSE, and CT were detected in 92 lung cancer patients by ELISA before operation. Thirty healthy volunteers were chosen as controls. Results The sensitivity of CA125, NSE, and CT for the diagnosis of lung cancer were 48.9%, 21.7%, and 7.6% respectively. The level of CA125 in lung cancer patients was significantly higher than that of control (P 0.05). Conclusion The diagnostic values of CA125, NSE and CT are limited. CA125 can be used as an prognostic parameter in patients with lung cancer after operation.

Details

Title
Diagnostic and prognostic values of serum CA125, NSE, CT levels in patients with lung cancer
Author
GUO, Zhanlin; QIU, Lin; ZHANG, Fengkun; YANG, Fude; Long, ZHAO; ZHANG, Yulong; ZHU, Xianming; QIU, Nengyong
Pages
206-208
Section
Clinical Research
Publication year
2003
Publication date
2003
Publisher
Chinese Anti-Cancer Association Chinese Antituberculosis Association
ISSN
10093419
e-ISSN
19996187
Source type
Scholarly Journal
Language of publication
Chinese
ProQuest document ID
2127759353
Copyright
Copyright © 2003. This work is published under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.